Qiagen N.V.

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-09-11 pm EDT			5-day change	1st Jan Change
45.84 ^USD	-0.13%		+3.80%	+2.38%

Sep. 11	QIAGEN NV : Berenberg reaffirms its Buy rating	ZD
Sep. 06	Centogene N.V. Announces Supervisory Board Resignations	CI

QIAGEN NV : Berenberg maintains a Buy rating

August 07, 2024 at 02:34 am EDT

Odysseas Manesiotis from Berenberg retains his positive opinion on the stock with a Buy rating. The target price differs slightly and is now set at EUR 54.90 versus EUR 54.20.

Latest news about Qiagen N.V.

QIAGEN NV : Berenberg reaffirms its Buy rating	Sep. 11	ZD
Centogene N.V. Announces Supervisory Board Resignations	Sep. 06	CI
Transcript : Qiagen N.V. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-06-2024 09:15 AM	Sep. 06
Eli Lilly: agreements signed with Qiagen and Genetic Leap	Sep. 05	CF
Such a long wait	Sep. 05
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday	Sep. 05	MT
Qiagen Partners with Eli Lilly to Develop Testing Panel for Alzheimer's Disease	Sep. 05	MT
Qiagen, Eli Lilly Collaborate on APOE Genotype Test for Alzheimer's Diagnosis	Sep. 04	MT
Qiagen N.V. Enters into A Collaboration with Eli Lilly and Company to Support the Development of A QIAstat-Dx In-Vitro Diagnostic to Detect APOE Genotypes Which Can Play A Role in the Diagnosis of Alzheimer?S Disease	Sep. 04	CI
Transcript : Qiagen N.V. Presents at 21st Annual Goldman Sachs European Medtech and Healthcare Conference, Sep-04-2024 09:00 AM	Sep. 04
Qiagen Places $500 Million of Convertible Bonds	Sep. 04	MT
Qiagen to Issue $450 Million of Convertible Bonds due 2031	Sep. 03	MT
Qiagen Expands Companion Diagnostics Collaboration with AstraZeneca	Aug. 29	MT
Qiagen Expands Master Collaboration Agreement with AstraZeneca	Aug. 28	MT
Berenberg Lifts Price Target on Qiagen to EUR54.90 From EUR54.20, Keeps Buy Rating	Aug. 07	MT
QIAGEN NV : Berenberg maintains a Buy rating	Aug. 07	ZD
UBS Adjusts Price Target on Qiagen to $50 From $46, Maintains Neutral Rating	Aug. 02	MT
QIAGEN NV : UBS reiterates its Neutral rating	Aug. 02	ZD
Transcript : Qiagen N.V., Q2 2024 Earnings Call, Aug 01, 2024	Aug. 01
QIAGEN : Healthy Q2; profitability guidance upgraded	Aug. 01
QIAGEN NV : Berenberg gives a Buy rating	Aug. 01	ZD
QIAGEN NV : Receives a Buy rating from Goldman Sachs	Aug. 01	ZD
Qiagen Q2 Adjusted Earnings, Net Sales Rise; Q3 Outlook Set, 2024 Guidance Increased	Jul. 31	MT
Qiagen N.V Reports Q2 EPS of $0.55 on Sales of $496 Million, vs CIQ Analyst Consensus of $0.52/Share on Sales of $495 Million	Jul. 31	MT
Qiagen N.V. Updates Earnings Guidance for the Full Year 2024	Jul. 31	CI

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees

5,900

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - BofA Conference

Related indices

STOXX Europe 600 Index (EUR) , DAX

More about the company